Global Natural Killer Cell Therapies Pipeline Insight Report 2021: 100+ Companies and 140+ Pipeline Drugs -

DUBLIN--()--The "Natural Killer Cell Therapies - Pipeline Insight, 2021" drug pipelines has been added to's offering.

This "Natural Killer Cell Therapies - Pipeline Insight, 2021" report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer Cell Therapies R&D. The therapies under development are focused on novel approaches to treat/improve Natural Killer Cell Therapies.

Natural Killer Cell Therapies Emerging Drugs Chapters

This segment of the Natural Killer Cell Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Natural Killer Cell Therapies Emerging Drugs

Monalizumab: Innate Pharma

Monalizumab (also known as IPH2201) is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic NK and CD8 T lymphocytes. It is under development by Innate Pharma in Phase III stage for the treatment of Squamous Cell Carcinoma of the Head and Neck and in Phase II stage of development for the treatment of gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. It is in the Phase I stage of development for the treatment of advanced solid tumors and hematological malignancies.

NKTR-214 (Bempegaldesleukin): Nektar Therapeutics

NKTR-214 is designed to grow specific cancer-killing T-cells and natural killer cell populations in the body that fight cancer is known as endogenous tumor-infiltering lymphocytes (TILs). NKTR-214 stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and Natural Killer (NK) cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of these effector T cells.

ALT 803: ImmunityBio

ALT 803 is a novel IL-15 superagonist complex, with improved pharmacokinetic properties and enhanced anti-tumor activity compared to recombinant human IL-15. It has also shown to potently activate human effector NK cells and enhance antibody-dependent cell-mediated cytotoxicity (ADCC) of anti-CD20 antibodies against human lymphoma cells in various tumor models. It is under development by Altor Bioscience Corporation and is currently in Phase II/III for Bladder Cancer.

It is in Phase II stage for the treatment of Acute Myelogenous Leukemia (AML); Non-muscle Invasive Blood Cancer, in Phase I/II stage for the treatment of Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndromes (MDS); Multiple Myeloma; Advanced Pancreatic Cancer; Non-small Cell Lung Cancer and Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma. It is in Phase I stage for the treatment of Human Immunodeficiency virus (HIV) and Melanoma, Renal Cell, and Squamous Cell Head and Neck Cancer. It is developed by using IL-15 Protein Super agonist and Scaffold Technology and is administered by intravenous route.


ALECSAT (Autologous Lymphoid Effector Cells Specific against Tumor-cells) is a therapy that supplements and strengthens the patient's immune system so it can fight the cancer cells in the same way as the body originally should have reacted. Natural Killer Cells used, in the ALECSAT therapy attack, the cancer cells in several ways, as they can recognize more than one property of the cancer cells. ALECAST is being evaluated for breast cancer and newly diagnosed glioblastoma in Phase II.

PNK-007: Celularity

PNK-007 is a human umbilical cord blood-derived, culture-expanded natural killer cell therapy. The umbilical cord has CD34+ cells that are differentiated and expanded up to 50,000 fold over 35 days in a good manufacturing process (GMP) compliant facility to produce 12 billion cells that are 85% pure for NK cells without the use of a feeder cell line. These cells can be aliquoted and frozen for use at a later date. The CDK derived NK cells have substantial cytolytic activity against several human tumor cell lines, primary AML, and primary multiple myeloma cells. PNK-007 successfully completed pre-clinical studies for acute myeloid leukemia (AML) and multiple myeloma (MM) and is being evaluated in Phase I for the treatment of acute myeloid leukemia and Glioblastoma. PNK-007 is administered intravenously and developed by Cellular Therapeutics.

Major Players in Natural Killer Cell Therapies

There are approx. 100+ key companies which are developing the therapies for Natural Killer Cell Therapies. The companies which have their Natural Killer Cell Therapies drug candidates in the most advanced stage, i.e. phase III include, Innate Pharma.

Key Questions Answered

  • How many companies are developing Natural Killer Cell Therapies drugs?
  • How many Natural Killer Cell Therapies drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Natural Killer Cell Therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Natural Killer Cell Therapies therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Natural Killer Cell Therapies and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • ImmunityBio
  • Five Prime Therapeutics
  • Innate Pharma
  • Nektar Therapeutics
  • Cantargia
  • CureTech
  • Dynavax
  • Cellid Company
  • Kiadis Pharma
  • Multimmune GmbH
  • CytoVac
  • XNK Therapeutics
  • NantKwest
  • Green Cross Corporation
  • HiberCell
  • Bristol-Myers Squibb
  • Innate Pharma
  • Affimed Therapeutics AG
  • Wugen
  • Abivax
  • Glycostem Therapeutics (IPD Therapeutic)
  • Synimmune
  • GT Biopharma
  • Bellicum Pharmaceuticals
  • Asclepius Technology Company Group
  • PersonGen BioTherapeutics (Suzhou)
  • Chongqing Sidemu Biotechnology
  • Artiva Biotherapeutics
  • NKMax
  • Acepodia
  • Allife Medical Science and Technology
  • Bright Path Biotherapeutics
  • Kuur Therapeutics (Formerly Cell Medica)

Key Products

  • ALT 803
  • Bemarituzumab
  • Monalizumab
  • NKTR-214 (Bempegaldesleukin)
  • Nidanilimab
  • Pidilizumab
  • SD-101
  • BVAC-C
  • PD-L1.t-haNK
  • K-NK002
  • Enkastim
  • CellProtect
  • Nk-92
  • haNk
  • MG4101
  • Imprime PGG
  • Lirilumab
  • IPH4102
  • AFM-13
  • WU-NK-101
  • ABX196
  • AFM24
  • PNK-007
  • Allogeneic Natural Killer Cell Therapy (oNKord)
  • KNK-ID-101
  • GTB-3550
  • CAR-NK cells
  • DF1001
  • DF-6002
  • NKG2D-ACE2 CAR-NK Cells
  • AB-101
  • SNK01
  • NKTR-225

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900